Upgrade to SI Premium - Free Trial

Regeneron Pharma (REGN) Thoughts After Speaking with Management - Truist Securities

January 12, 2021 6:52 AM
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $770.00 price target on Regeneron Pharma (NASDAQ: REGN) after speaking ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments